Open AccessClinical Practice Changes After Post-Market Safety Reports on Desmopressin Orally Disintegrating Tablet in Japan: A Single-Center Retrospective Study
Author(s) -
Takuma Yasuda,
Takaaki Murakami,
Akihiro Yasoda,
Masakatsu Sone,
Norio Harada,
Mariko Ogura,
Nobuya Inagaki
Publication year - 2021
Publication title -
journal of clinical medicine research
Language(s) - English
Resource type - Journals
eISSN - 1918-3011
pISSN - 1918-3003
DOI - 10.14740/jocmr4399
Subject(s) - desmopressin , medicine , hyponatremia , single center , retrospective cohort study , adverse effect , nasal administration , anesthesia , urology , gastroenterology , pharmacology
Desmopressin orally disintegrating tablet (ODT) was approved in March 2012 in Japan; the post-market safety reports, which warned about adequate initial dose of desmopressin ODT, were published in 2014. However, it is unclear how the warning affected physician and patient behavior.